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Abstract 
Roflumilast is a first-in-class oral selective anti-inflammatory drug which is a PDE4 inhibitor. It has been 
approved by regulatory authorities in the Europe and US in 2010 and 2011 respectively for the prevention of acute 
exacerbations among patients with severe COPD. Since then, the drug has been studies in different populations in 
clinical trials as well as real world studies. The studies looked at different end points such as the quality of life, 
improvement in spirometry indices as well as the ability of the drug to prevent exacerbations and hospital 
admissions. There was a variable response seen in these studies.  This article seeks to review the evidence for the 
role of roflumilast in COPD from these recent studies since its approval.  
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Introduction  
 
Chronic obstructive pulmonary diseaseis currently the 
third leading cause of death globally and is purported 
to become the most common cause of death within the 
next decade. [1]Smoking is the principal risk factor of 
COPD [2]. Bronchodilators and anti-inflammatory 
agents are currently used in the pharmacologic 
management of COPD. Bronchodilators such as beta 
agonists and muscarinic antagonists are useful for 
symptom relief but may not have many roles in 
preventing the progression of disease[3]. Inhaled 
corticosteroids are useful in preventing exacerbations 
and have also shown to improve the quality of life in 
COPD. However, they do not improve mortality or 
lung function even with long term usage[4]. 
Methylxanthines may be an alternative option in these 
patients but have limited efficacy[5]. Thus, COPD does 
appear to be a condition that requires better drugs 
which offer more than what the current battery of drugs 
offers.  
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Roflumilast is a first-in-class molecule, a 
phosphodiesterase-4 (PDE-4) inhibitor that was 
approved by the US FDA for the management of 
COPD. This article attempts to review the evidence 
from the literature on its efficacy, safety, and the 
current status of the molecule in the management of 
COPD.  
Mechanism 
Phosphodiesterases (PDE)is a large enzyme family 
whichis subdivided into eleven (PDE1 –PDE11) 
different isoforms [6].Inhibition of phosphodiesterase 
will increase cyclic guanosine monophosphate 
(cGMP)  and cyclic adenosine monophosphate (cAMP) 
which act intra-cellularly for anti-inflammatory action 
[7]. Second messenger (cAMP) will act on airway 
smooth muscle and lead to inhibition of inflammatory 
mediators [8].  PDE4 inhibitors will affect the action of 
immune agents and prevent neutrophil inflammation 
and act through various pathways for anti-
inflammation action [9].Roflumilastis a PDE-4inhibitor 
which inhibits the breakdown of cAMP into adenosine 
monophosphate(AMP). This results inthe accumulation 
of intracellular cAMP [10]. PDE-4 inhibitors with ICS 
will reducecytokinerelease and increase the anti-
inflammatory effect in CD8+ cells [11]. Roflumilast 
decreases the pulmonary inflammation of the lungs by 
reducing the prolylendopeptidase and acetyl-proline-
glycine-proline level in sputum [12].Roflumilast 
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reduces inflammation in the airway by inhibiting 
endotoxin-induced various macrophages such as 
eosinophil, neutrophil, and improve lung function. [13] 
Pharmacokinetics 
After administeringa single oral dose of roflumilast, 
absorption is quick with the bioavailability of 80% 
(approximately) and its metabolism occurs through the 
liver [7].Roflumilast reaches peak concentration in 
plasma within one hour and is highly bound to proteins 
in plasma[14].Food does not inhibit roflumilast activity 
but it will delay Tmax by 0.9 hrs and reduce Cmax by 
20% [15]. In patients, compared with various doses of 
roflumilastadministered, 500µg of roflumilast was 
found to improve FEV1of patients [16].  
Pharmacokinetics of roflumilast 500µg on concomitant 
administration with 10mg montelukast in steady 
conditionsremains unchanged [17]. 
Efficacy 
Since its regulatory approval,roflumilast has been 
evaluated in several clinical trials and real-world 
studies. In a study by Criner et al, 64 patients having 
moderate to severe COPD were randomized to receive 
roflumilast or placebo. It was observed, that therewas 
no difference in the time for first readmission or death 
between the two groups. There was no difference in the 
quality of life, as assessed by St. George’s Respiratory 
Questionnaire. There were no differences in the total 
number of re-hospitalizations in either group [18]. 
DINO and DACOTA were two prospective 
observational studies that were performed in patients 
with severe to very severe COPD, to receive new 
treatment with roflumilast 500µg once daily. These 
studies were carried out in the German population. 
Randomized controlled trials have a limitation of not 
being representative of daily practice. For instance, 
there is a greater than average treatment adherence in 
RCTs than clinical practice. There is also an 
unsurprisingly greater predilection to use surrogate 
endpoints than hard endpoints in clinical trials. It has 
been argued, that the quality of life, is a better indicator 
of the patient’s perception and experience with respect 
to a particular drug therapy. In this context, the DINO 
and DACATO studies chose to evaluate principally the 
quality of life in users of roflumilast. Change in clinical 
COPD questionnaire total score, from the baseline, 
following roflumilast intake was considered the 
primary end point. The minimal clinically important 
difference for the above end point was fixed at 0.41. 
Secondary endpointsincluded changes in CCQ 
(Clinical COPD questionnaire) domain scores, COPD 
Assessment Test (CAT) and, Post Bronchodilator 
FEV1. Approximately 9000 patients were included in 
the two studies. Treatment with roflumilastshowed an 
improvement in the CCQ total and domain scores 
greater than the prefixed MCID (minimal clinically 
important difference). There was also a significant 
improvement in the CAD score at 6 months. Patients 
with frequent exacerbation had a greater benefit with 
roflumilast than those with non-frequent exacerbation. 
There was also a much greater improvement in the 
post-bronchodilator FEV1in the DACOTA study, than 
what was earlier observed in RCTs (200ml over 6 
month vs 50ml over a year). More than one-third of 
participants in both the studies discontinued therapy 
with roflumilast. This is consistent with that seen in 
earlier RCTs [19].In a study by Martinez et al, 
conducted in patients with severe to very severe COPD 
with a history of two or more exacerbations or 
hospitalized in the preceding year, roflumilast was 
evaluated for its effect on the frequency of 
exacerbations. All these patients continued to receive 
inhaled corticosteroids/ LABA with or without LAMA 
within 3 or 4 months. Patients (n=2354) were 
randomised to receive either roflumilast 500µg once 
daily or placebo in a 1:1 ratio for 52 weeks in a double-
blind manner. At the end of 1 year, it was noted that 
roflumilast did not have any substantial effect in 
preventing exacerbation in comparison with placebo. 
Only patients with a history of more than 3 
exacerbations and or one or more prior hospitalization 
showed a reduction in the rate of exacerbation. The 
discontinuation rate with roflumilast was almost double 
that seen with placebo (11.7 vs 5.4). These findings are 
not in agreement with the earlier (REACT Study). In 
the REACT study, there was a significant reduction in 
the rate of severe and moderate exacerbation when 
compared to placebo. One major difference between 
the (RE
2
SPOND Study) and REACT Study, was the 
higher number of patients having past history of 
repeated exacerbation.(25 vs 11 %).Thus roflumilast 
appears to be ideally suited for those patients with 
moderate to severe exacerbations and those with past 
history of more than three exacerbations [20]. 
Lee et al undertook a double blind randomized control 
trial in Korean patients with COPD. A total of 207 
participants were randomized to receive roflumilast or 
placebo. At the end of 12 weeks, there was an increase 
in the least square means of the post-bronchodilator 
FEV1 by 43ml and it reduced by 60ml among users of 
placebo (p=0.001). However, patients-centric outcomes 
including quality of life, exercise, and dyspnoea were 
not evaluated. The low sample size and lack of female 
participants in the study hampered the generalizability 
of these findings. [21] 
In a study by Liu et al,roflumilast was evaluated in 
Chinese patients with COPD for atleast 12 months,who 
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also had a history of being clinically stable for atleast 
one month before the study. Patients were randomized 
to receive roflumilast or placebo. FVC, FEV1, FEF25-
75% showed improvement in the roflumilast in 
comparison with placebo at the end of 12 months and 
as well as 3 months after stopping the treatment. There 
was also a lowering of the total SGRQ score in the 
roflumilast group in comparison with the placebo. This 
trial was fraught with certain limitations such as being 
a single centre and restricted to the Chinese Han 
ethnicity. [22] 
Safety 
In real-world study, alow percentage of discontinuation 
occurred during treatment due to adverse events,among 
patients with COPD receiving 250μg of roflumilast 
than500μg of roflumilast. [23]Common adverse effects 
include anorexia, nausea, headache,and weight loss. No 
life-threatening adverse effectswere reported [23,24]. 
However, there is a risk of suicidal ideation and 
behaviour based on post-marketing reports and one 
should exercise prudence in prescribing drugs in 
patients with depression or other risk factors for 
suicide. [25] 
 
Table 1:Some Important studies which based on Roflumilast 
Current status 
Corresponding 
Author 
Year Sample 
Size 
Country Duration Interventional 
Group 
Control 
Group 
Result 
 
 
 
 
 
 
 
Sang-Do Lee 
[21] 
 
 
 
 
 
 
 
2015 
 
 
 
 
 
 
 
260 
 
 
 
 
 
 
 
Korea 
 
 
 
 
 
 
 
12 weeks 
 
 
 
 
 
 
 
Roflumilast 
(500 µg) 
 
 
 
 
 
 
 
Placebo 
 
Among Korean patients with 
moderate to severe COPD, lung 
activity was found to have 
improved significantly in 
spirometry. End points like 
pre/post bronchodilator FEV, 
FVC,peak expiratory flow on 
roflumilast group with no 
tolerability issue was raised.  
 
 
 
 
 
 
 
Martinez 
 [29] 
 
 
 
 
 
 
 
2016 
 
 
 
 
 
 
 
1178 
 
 
 
 
 
 
 
U S 
 
 
 
 
 
 
 
52 weeks 
 
 
 
 
 
 
 
Roflumilast 
(500 µg) 
 
 
 
 
 
 
 
Placebo 
 
Roflumilastwas found to 
improvethe lung activity and 
decreasedexacerbation in 
individuals with history of 
hospitalizationwhich was not 
statistically significant 
(CI:0.8-1.04,  P= 0.163) 
 
 
 
Hakan-Gunen 
[30] 
 
 
2019 
 
 
83 
 
 
Turkey 
 
 
18 
months 
 
 
Roflumilast 
500µg  
 
 
Nil 
 
 
 
Decreased COPDexacerbation 
(P<0.001) and hospitalization 
(P<0.001) was reported in 
patients receivingroflumilast 
compared to earlier treatment.  
 
 
 
 
 
Dan Peng [31] 
 
 
 
 
 
2018 
 
 
 
 
 
120 
 
 
 
 
 
China 
 
 
 
 
 
12 
months 
 
 
 
 
 
Roflumilast 
500µg 
 
 
 
 
 
Placebo 
 
In this real world study, after 
three and twelve month of follow-
up, lung activity was improved 
and FEV, FEF, FVC was 
considerably better from the 
baseline value,roflumilast at 
5mg/kg significantly decreased 
post-PAE microvascular 
hyperpermeability (P < 0.05) 
compared with control.Also, 
SGRQ scale, quality of life 
among roflumilast group was 
found to be improved. 
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Roflumilast has been approved by FDA in 2011 and 
approved by European Medicines Agency on April 2010 
for the treatment of severe COPD with chronic bronchitis 
[26]. In India, 2014,CDSCO approved roflumilast for the 
maintenance management of COPD associated with 
bronchitis[27]. In India,the estimated price of one strip (10 
Tab) of roflumilast isaround Rs 125/-[28]. There are seven 
on-going trials based on roflumilastwhich are currently 
recruiting patients in various indications such as chronic 
bronchitis,asthma,obesity,lymphoma, bronchiectasis, and 
chronic plaque psoriasis [32]. 
 
Conclusion 
Roflumilastis an oral drug approved for 
preventing exacerbations in severe COPD that are 
associated with chronic bronchitis and who have a history 
of frequent exacerbations. This could be a valuable 
alternative when patients do not respond to the 
combination of LABA and LAMA. The high 
discontinuation rate in trials does not give much 
confidence for prescribers to choose this molecule. 
However, it remains to be seen if roflumilast could in 
future replace the first-line drugs for the management of 
the earlier stages of the disease.  
      Abbreviation 
REACT-Roflumilast and Exacerbations in Patients 
Receiving Appropriate Combination Therapy 
FDA-Food and drug administration 
CDSCO-Central Drugs Standard Control Organisation 
ICS-Inhaled corticosteroid 
AE- Adverse event 
cAMP-Cyclic adenosine monophosphophate 
 
 
 
References 
1. Vestbo J, Hurd SS, Agustí AG, Jones PW, 
Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, 
Martinez FJ, Nishimura M, Stockley RA. Global 
strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary 
disease: GOLD executive summary. American 
journal of respiratory and critical care medicine. 
2013;187(4):347-65. 
2. Caramori G, Ruggeri P, Di Stefano A, Mumby S, 
Girbino G, Adcock IM, Kirkham P. Autoimmunity 
and COPD: clinical implications. Chest. 2018; 
153(6):1424-31. 
3. Putcha N, Wise RA. Medication Regimens for 
Managing COPD Exacerbations. Respiratory care. 
2018;63(6):773-82. 
4. Tashkin DP, Strange C. Inhaled corticosteroids for 
chronic obstructive pulmonary disease: what is 
their role in therapy?. International journal of 
chronic obstructive pulmonary disease. 
2018;13:2587. 
5. Lee JK, Rhee CK, Kim K, Ra SW, Lee JH, Jung 
KS, Yoo KH, Kim YI, Kim DK. Prescription 
Status and Clinical Outcomes of Methylxanthines 
and Leukotriene Receptor Antagonists in Mild-to-
Moderate Chronic Obstructive Pulmonary Disease. 
International Journal of Chronic Obstructive 
Pulmonary Disease. 2019;14:2639. 
6. Phillips JE. Inhaled Phosphodiesterase 4 (PDE4) 
Inhibitors for Inflammatory Respiratory Diseases. 
Frontiers in Pharmacology. 2020;11:259. 
7. Tashkin DP. Roflumilast: the new orally active, 
selective phophodiesterase-4 inhibitor, for the 
treatment of COPD. Expert opinion on 
pharmacotherapy. 2014;15(1):85-96. 
8. Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev 
VO, Schmidt M. Phosphodiesterases as therapeutic 
targets for respiratory diseases. Pharmacology & 
therapeutics. 2019;197:225-42. 
9. Al-Sajee D, Yin X, Gauvreau GM. An evaluation 
of roflumilast and PDE4 inhibitors with a focus on 
the treatment of asthma. Expert opinion on 
pharmacotherapy. 2019;20(5):609-20. 
10. Conti M, Beavo J. Biochemistry and physiology of 
cyclic nucleotide phosphodiesterases: essential 
components in cyclic nucleotide signaling.Annu. 
Rev. Biochem.. 2007;76:481-511. 
11. Grundy S, Plumb J, Kaur M, Ray D, Singh D. 
Additive anti-inflammatory effects of 
corticosteroids and phosphodiesterase-4 inhibitors 
in COPD CD8 cells. Respiratory research. 
2016;17(1):9. 
12. Wells JM, Jackson PL, Viera L, Bhatt SP, Gautney 
J, Handley G, King RW, Xu X, Gaggar A, Bailey 
WC, Dransfield MT. A randomized, placebo-
controlled trial of roflumilast. Effect on proline-
glycine-proline and neutrophilic inflammation in 
chronic obstructive pulmonary disease. American 
journal of respiratory and critical care medicine. 
2015;192(8):934-42.\ 
13. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, 
Côté J, Duong M, Killian KJ, Milot J, Deschesnes 
F, Strinich T, Watson RM, Bredenbröker D. 
Roflumilast attenuates allergen-induced inflame-
mation in mild asthmatic subjects. Respiratory 
research. 2011;12(1):140. 
14. Huang J, Fu CX, Yang XY, Cui C, Yang S, Kuang 
Y, Guo CX, Hu P, Pei Q, Yang GP. 
Pharmacokinetics of single-and multiple-dose 
International Journal of Health and Clinical Research, 2020;3(5):85-89                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
George                    International Journal of Health and Clinical Research, 2020; 3(5):85-89 
www.ijhcr.com                              
                    89 
 
roflumilast: an open-label, three-way crossover 
study in healthy chinese volunteers. Drug design, 
development and therapy. 2018;12:4047. 
15. Li Q, Wang Y, Liu L, Ma P, Ding L. Pharma-
cokinetics of roflumilast and its active metabolite 
roflumilast N-Oxide in healthy Chinese subjects 
after single and multiple oral doses. European 
journal of drug metabolism and pharmacokinetics. 
2017;42(3):371-81. 
16. Meltzer EO, Chervinsky P, Busse W, Ohta K, 
Bardin P, Bredenbröker D, Bateman ED. 
Roflumilast for asthma: efficacy findings in 
placebo-controlled studies. Pulmonary pharma-
cology & therapeutics. 2015;35:S2 
17. Bateman ED, Goehring UM, Richard F, Watz H. 
Roflumilast combined with montelukast versus 
montelukast alone as add-on treatment in patients 
with moderate-to-severe asthma. Journal of 
Allergy and Clinical Immunology. 2016; 
138(1):142-9. 
18. Criner GJ, Jacobs MR, Zhao H, Marchetti N. 
Effects of Roflumilast on Rehospitalization and 
Mortality in Patients. Chronic Obstructive 
Pulmonary Diseases: Journal of the COPD 
Foundation. 2019;6(1):74. 
19. Kardos P, Mokros I, Sauer R, Vogelmeier CF. 
Health status in patients with COPD treated with 
roflumilast: two large noninterventional real-life 
studies: DINO and DACOTA. International 
journal of chronic obstructive pulmonary disease. 
2018;13:1455. 
20. Martinez FJ, Calverley PM, Goehring UM, Brose 
M, Fabbri LM, Rabe KF. Effect of roflumilast on 
exacerbations in patients with severe chronic 
obstructive pulmonary disease uncontrolled by 
combination therapy (REACT): a multicentre 
randomised controlled trial. The Lancet. 
2015;385(9971):857-66. 
21. Lee JS, Hong YK, Park TS, Lee SW, Oh YM, Lee 
SD. Efficacy and safety of roflumilast in Korean 
patients with COPD. Yonsei medical journal. 
2016;57(4):928-35. 
22. Liu DY, Wang ZG, Gao Y, Zhang HM, Zhang 
YX, Wang XJ, Peng D. Effect and safety of 
roflumilast for chronic obstructive pulmonary 
disease in Chinese patients. Medicine. 2018; 
97(7):13 
23. Joo H, Han D, Lee JH, Rhee CK. Incidence of 
adverse effects and discontinuation rate between 
patients receiving 250 micrograms and 500 
micrograms of roflumilast: a comparative study. 
Tuberculosis and respiratory diseases. 2018; 
81(4):299-304. 
24. Hwang H, Shin JY, Park KR, Shin JO, Song KH, 
Park J, Park JW. Effect of a dose-escalation 
regimen for improving adherence to roflumilast in 
patients with chronic obstructive pulmonary 
disease. Tuberculosis and respiratory diseases. 
2015;78(4):321-5.. 
25. Bazaldu OV, Davidson DA, Babb FC. Roflumilast 
(Daliresp) for chronic obstructive pulmonary 
disease. American family physician. 2014; 
15;89(4):300-1. 
26. Giembycz MA, Field SK. Roflumilast: first 
phosphodiesterase 4 inhibitor approved for 
treatment of COPD. Drug design, development 
and therapy. 2010;4:147. 
27. https://cdscoonline.gov.in/CDSCO/Drugs/Roflumi
last . 
28. Latest price of roflumilastin india. Available from 
URL:  https://www.netmeds.com/ prescriptions/ 
rofshield-tablet-10-s 
29. Calverley PM, Rabe KF, Goehring UM, 
Kristiansen S, Fabbri LM, Martinez FJ. 
Roflumilast in symptomatic chronic obstructive 
pulmonary disease: two randomised clinical trials. 
The Lancet. 2009 ;374(9691):685-94. 
30. Cilli A, Bal H, Gunen H. Efficacy and safety 
profile of roflumilast in a real-world experience. 
Journal of thoracic disease. 2019;11(4):1100. 
31. Liu DY, Wang ZG, Gao Y, Zhang HM, Zhang 
YX, Wang XJ, Peng D. Effect and safety of 
roflumilast for chronic obstructive pulmonary 
disease in Chinese patients. Medicine. 2018;97(7). 
32. Current Roflumilast studies from clinical trial, 
Available from URL :https://clinicaltrials. 
gov/ct2/results? cond=&term= Roflumilast& cntry 
= &state=&city=&dist=&recrs=a 
Source of Support:Nil 
Conflict of Interest: Nil 
